The use of fecal calprotectin in detecting immunotherapy induced colitis and feasibility for the use of immunohistochemical markers in patients receiving checkpoint inhibitors’- a pilot study

Primary: To determine fecal calprotectin levels in patients treated with checkpoint inhibitors.

To analyse whether fecal calprotectin is a useful marker in distinguishing colitis from diarrhoea with other causes and whether fecal calprotectin is a useful marker for early detection of colitis.

study will be completed if 8 patients with colitis will be included in the study

Participants are asked to collect feces every two or three weeks (depending on the interval of the administration of the immunotherapy) starting prior to the first cycle of immunotherapy until 2-3 weeks after the last cycle. They will be questioned every 2-3 weeks (either during regular visits or by means of a telephone call) about gastro-intestinal symptoms.

If patients experience gastrointestinal symptoms which may indicate colitis a colonoscopy with at least 10 biopsies will be performed